NEW YORK--(BUSINESS WIRE)--Omrix Biopharmaceuticals, Inc. (“Omrix” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today provided a corporate update on its key businesses and products, preliminary unaudited revenues for the fourth quarter and year-ended December 31, 2007 and 2008 full year guidance.
